Poor Gadoxetate Disodium Hepatobiliary Enhancement in MRI of Patients with Cirrhosis: Factors for Prediction
Amelia Wnorowski 1 , Flavius Guglielmo 1 , Laurence Parker 1 , Sandeep Deshmukh 1 , Patrick O'Kane 1 , Christopher Roth 1 , and Donald Mitchell 1
Radiology, Thomas Jefferson University
Hospital, Philadelphia, PA, United States
Gadoxetate disodium is a useful MRI contrast agent for
the diagnosis of hepatocellular carcinoma in cirrhosis.
Its use is limited by poor hepatic and biliary
enhancement in some patients. The purpose of this study
was to identify predictors of poor enhancement, which
was assessed in 91 cirrhotic patients and compared to
various laboratory parameters, liver length and degree
of ascites. A correlation matrix was performed, followed
by multiple and logistic regressions. Several variables
independently correlated with enhancement. However, the
first variable chosen, either albumin or MELD score,
accounted for almost all of the variance in the model.
This abstract and the presentation materials are available to members only;
a login is required.